Iscador is a preparation made from European mistletoe. When exposed to it, some tumours and T- cells commit suicide, or apoptosis. Iscador has been injected under the skin in subjects with cancer, causing some tumours to shrink and some subjects to experience remission. It is difficult to assess Iscador's usefulness as an anti-cancer agent, however, because most reports on the drug are written in German. We were unable to find articles in the English-language literature comparing the effect of Iscador with that of cancer chemotherapy.
Iscador's effect on the immune system has been the object of study. In subjects with cancer, increased levels of CD4+ and natural killer cells have been reported while, strangely, levels of CD8+ cells decrease. We now report the results from a phase I/II study of the drug in people with HIV/AIDS.
Researchers reported data on 32 HIV-positive subjects (two female, 30 male) as well as on nine non-HIV-infected subjects. The CD4+ counts of the HIV-positive subjects ranged between 50 and 600 cells; viral load measures were not provided. Some subjects used AZT, ddI or ddC as well as antibiotics to prevent PCP (Pneumocystis carinii pneumonia) during the study.
All subjects received Iscador injected under the skin twice weekly. Some subjects took the drug for up to 68 weeks. The doses used in the study ranged from 0.01 to 5 milligrams (mg) per kilogram of body weight per day.
Iscador did not appear to affect levels of CD4+, CD8+ or other lymphocytes during the study.
All HIV-positive subjects experienced decreased levels of red blood cells. The decrease was greatest in those subjects receiving Iscador at doses ranging of 1 to 2 mg. At that dose, the decrease in red blood cells was statistically significant: not likely due to chance alone.
Iscador did not cause any detectable liver toxicity, but slight kidney damage did occur in all HIV-positive subjects. The evidence of this damage was higher-than-normal levels of creatinine in the blood. All subjects developed a small but significant decrease in the level of protein in the blood, possibly caused by the kidney damage.
At high doses, 13 subjects developed inflammation, according to the researchers. The inflammation took the form of the following conditions:
Iscador also may have caused the following symptoms:
No subject developed a life-threatening illness during the study.
Points to consider:
Major unanswered questions include the following:
We hope that answers to these questions will come from other studies.
A smaller study of Iscador looked at the drug's effect on production of interferon-gamma (IFN-gamma), a cytokine needed to help the immune system fight HIV. Iscador injections caused no increase in IFN-gamma levels. This result is not promising and may explain why an increased CD4+ cell count was not seen in the larger study of Iscador.
Another study of Iscador is currently under way. The doctors involved will measure viral load. This fact is important, because Iscador clearly stimulates the immune system, and this stimulus may increase viral load.
1. Gorter RW, van Wely M, Reif M and Stoss M. Tolerability of an extract of European Mistletoe among immunocompromised and healthy individuals. Alternative Therapies in Health and Medicine 1999;5(6):37-48.
2. Stoss M and Gorter RW. No evidence of INF-gamma increase in the serum of HIV-positive and healthy subjects after subcutaneous injection of a non-fermented viscum album L. extract. Natural Immunity 1999;16(4):157-164.
3. Stoss M, van Wely M, Musielsky H and Gorter RW. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks. Arzneimittelforschung 1999;49(4):366-373.
4. Ernst E and Cassileth BR. How useful are unconventional cancer treatments? European Journal of Cancer 1999;35(11):1608-1613.
5. Stein GM and Berg PA. Flow cytometric analyses of the specific activation of peripheral blood mononuclear cells from healthy donors after in vitro stimulation with a fermented mistletoe extract and mistletoe lectins. European Journal of Cancer 1999;34(7):1105-1110.
6. Shimizu J, Yamazaki S and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumour immunity and autoimmunity. Journal of Immunology 1999;163:5211-5218.
7. Imami N, Antonopoulos C, Hardy GAD,e t al. Assessment of Type 1 and Type 2 cytokines in HIV Type-1-infected individuals: impact of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses 1999;15(17):1499-1508.
8. Thurner B, Haendle I, R der C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. Journal of Experimental Medicine 1999;190(11):1669-1678.
9. Dockrell DH, Badley AD, Algeciras-Schimnich A, et al. Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number. AIDS Research and Human Retroviruses 1999;15(17):1509-1518.
20000101
CATE10407
Copyright © 2000 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca
Disclaimer: The editors have taken all such care as they consider reasonable in preparing this database, but they cannot be held responsible for any inaccuracies or mis-statements of fact contained herein. Inclusion in this database of any information on any treatment, therapy, or clinical trial in no way represents an endorsement of that treatment, therapy, or trial by ÆGiS or any of its sponsors. This data should always be used in conjunction with professional medical advice.